Niacin-ER may be overlooked cause of thrombocytopenia

Niacin-ER may be overlooked cause of thrombocytopenia

(HealthDay)—Extended-release (ER) niacin is associated with progressive and reversible thrombocytopenia, according to a letter to the editor published online March 25 in the American Journal of Hematology.

Casey O' Connell, M.D., from the Keck School of Medicine of the University of Southern California in Los Angeles, and colleagues describe four (average age, 68.8 years) who were on niacin-ER for 20 months to nine years. All four patients developed progressive thrombocytopenia.

The researchers found that platelets recovered quickly after cessation of niacin-ER, with improvement noted within a month of cessation in all four patients. Based on criteria to determine the level of evidence for a causal association, three patients were found to have a "probable" association and one a "definite" association. The patients were on niacin-ER daily for 59 months, on average, at a median dose of 2,250 mg. Platelets recovered by an average of 91.5 × 109/L, with a mean time to response of 136 days. In two of the four patients who were anemic as well as thrombocytopenic, there was a marked improvement in hemoglobin upon discontinuation of niacin-ER.

"In conclusion, Niacin-ER is known to cause reversible thrombocytopenia, but this effect may be insidious and severe and can be accompanied by reversible anemia, both of which may be easily overlooked in with multiple medical conditions and concomitant medications," the authors write.

More information: Full Text (subscription or payment may be required)

Journal information: American Journal of Hematology

Copyright © 2016 HealthDay. All rights reserved.

Citation: Niacin-ER may be overlooked cause of thrombocytopenia (2016, April 10) retrieved 5 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

ACC: Niacin/Laropiprant no benefit in vascular disease


Feedback to editors